DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2011/0165096 A1 Liu Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2011/0165096 A1 Liu Et Al US 2011 01 65096A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0165096 A1 Liu et al. (43) Pub. Date: Jul. 7, 2011 (54) FICUS EXTRACTS HAVING ANGIOGENESIS Publication Classification HIBITING ACTIVITY AND METHODS OF (51) Int. Cl. SOLATING AND USING THE SAME A6IR 9/12 (2006.01) A636/00 (2006.01) CI2O 1/02 (2006.01) (75) Inventors: Zhijun Liu, Baton Rouge, LA A6IP35/00 (2006.01) (US); Eugene A. Woltering, A6IP3L/00 (2006.01) Kenner, LA (US) A6IP3L/04 (2006.01) A6IP37/00 (2006.01) A6IP27/02 (2006.01) (73) Assignee: ULLMAN MEDICAL, INC., A6IP 9/02 (2006.01) Silver Spring, MD (US) A6IP3/10 (2006.01) A6IP 7/02 (2006.01) A6IP 7/06 (2006.01) A6IP3/04 (2006.01) (21) Appl. No.: 13/058,957 A6IP4/00 (2006.01) A6IP 9/12 (2006.01) A6IP 9/00 (2006.01) (22) PCT Filed: Aug. 14, 2009 A6IPI/00 (2006.01) (52) U.S. Cl. .............................. 424/45; 424/725; 435/29 (86). PCT No.: PCT/USO9/53860 (57) ABSTRACT The present invention is directed to methods for extracting S371 (c)(1), and isolating extracts having angiogenesis inhibiting activity (2), (4) Date: Mar. 17, 2011 from a latex-containing portion of a Ficus variant, pharma ceutical and nutraceutical compositions comprising the extracts, methods of administering the extracts to treat angio Related U.S. Application Data genesis-dependent diseases and to reduce or inhibit neovessel growth in a Subject in need thereof, and the use of the extracts (60) Provisional application No. 61/088.924, filed on Aug. in the manufacture of a composition for reducing or inhibiting 14, 2008. neovessel growth. Patent Application Publication Jul. 7, 2011 Sheet 1 of 23 US 2011/O165096 A1 100 FIG. 1 Patent Application Publication Jul. 7, 2011 Sheet 2 of 23 US 2011/O165096 A1 Discard Solids S/S 22 225 M liquid Extract 24 are - P -- a Organic Fraction (F) Y242 Aqueous Extract (F) \ 43 Diluted Aqueous Extract Column Fractionation Eluted with DE HO (Fo) 27 Eluted with EtOH:HO (Fass) \)72 FIG. 2 Patent Application Publication Jul. 7, 2011 Sheet 3 of 23 US 2011/O165096 A1 300 312 31 FIG. 3A FIG. 3B Patent Application Publication Jul. 7, 2011 Sheet 4 of 23 US 2011/O165096 A1 4OO Mean Angiogenic Index = 1+1+1+1 = 4 FIG. 4A Mean Angiogenic Index = 4+4+4+4 = 16 FIG. 4B Patent Application Publication Jul. 7, 2011 Sheet 5 of 23 US 2011/O165096 A1 Mean Angiogenic Index (Ficus carica L., variety kadota, day 14) (series 1A) DExcluding Zeros DIncluding Zeros d s 3 3 38 g 3 E 3 E st S S SS2 S. S. C. S. C. S. w CN o S CN o S (NE (NE da o da C) 8 C N). C C N C C N1 N1 a E a E as CD go 8 cc E S C8 d). g 3- it c. it c. d d Treatment FIG. 5A Angiogenesis Initiation (%) 80 (Ficus carica L., variety kadota, day 14) (series 1A) 70 – 60 - 9. 50 – S. 30 — is 20 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 10 – O 9 £ 35, 35 S.F S.F D - - s s - N N CN E CN E cN SC) cN EC. CC N4 W- N1 cy a N1 Na N1 O CD o o O) Co Oc C. v . C. c. 3-es ifC S ifC S H- O H- C C O Treatment FIG. 5B Patent Application Publication Jul. 7, 2011 Sheet 6 of 23 US 2011/O165096 A1 Mean Angiogenic Index 11 (Ficus carica L., variety kadota, day 14) (series 1B) - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - DIncluding(IDExcluding Zeros Zeros g 3 - S - 3 3 S 3 s 58 C w CN o S CN o S C E N CN c es CD go 8 cc E o O3 d g 3. in c. in c. O O Treatment F.G. 6A Angiogenesis initiation (%) 70 ----------------------------- (Ficus carica L., variety kadota, day 14) (series 1B). 60 - Initiati to 50 40 30 - S. 20 - 10 O – s- St3 E- S3 2 - S.3 SS. SR3 5 SESS SS38 8 CC N2 R S S2 C. S & N1 N2 E S2 es CD go 8 cc odd O3 g . o st- it c ic O C Treatment F.G. 6B Patent Application Publication Jul. 7, 2011 Sheet 7 of 23 US 2011/O165096 A1 Mean Angiogenic Index (Ficus carica L., variety kadota, day 14) (series 1C) DExcluding Zeros DIncluding Zeros 5 C CC CC cd CO - CO - 9 "as 9 - 9 - - & E SE O E O E C c 8 CN go S CN go S S S cN 9) cN 9) 3 N. C. S & C S N) Y S. E S. E as go E go E is .95 g St. CD in c. - CS C C Treatments Angiogenesis Initiation (%) (Ficus carica L., variety kadota, day 14) (series 1C) Initiation 9 C5 SCO SCO SE SE go(O -8 goCO -8 E < e SS E S 3 S 2 S 2 SS, SS 3 S. S N. C. raS. Na Q S.9 N)S. Y.SS N2 E & E St.ea CD go g g os 23cs g g g Treatment FIG. 7B Patent Application Publication Jul. 7, 2011 Sheet 8 of 23 US 2011/O165096 A1 Mean Angiogenic Index (Ficus carica L., variety kadota, day 14) (series 1D) 3 |Excluding Zeros DIncluding Zeros 2 1 O d s InS S SE L.SE SE SE t E 9 W- Scy O Gs O Gs O S. O S. w- & S & SS Sg Sg N. O. N to 8 a. a S. g. a g a N2 E Na E as (5 E () E (p & D8 (p (p 2 3t - C - O C C Treatments FIG. 8A Angiogenesis initiation (%) 30 (Ficus carica L., variety kadota, day 14) (series 1D) 25 - Initiation 20- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 15 - d 10 al O s g g E gE SE SE SE S SS, SS SS SS SS SS O - cN S CN S E SE Na E & E C k N. W. M cy) - cy) - cy 1. CD isOS isC 9. it9 cC. isop C it 2 itS2' Ye' C P Treatments FI G Patent Application Publication Jul. 7, 2011 Sheet 9 of 23 US 2011/O165096 A1 Mean Angiogenic Index (Ficus carica L., variety kadota, day 14) (series 1E) T Excluding Zeros DIncluding Zeros 234.5671 O C C CC CC C - CC - 9 C C as E as 8 S E S E w-C - &92 - Sc. &92 38cyd SgC is SgC is CNo Sto CNo Sto 8--a CDCC YgDo goa 2 gE gasa opY 8 S^p. S N.p S2 3t - - C C C C Treatments FIG. 9A Angiogenesis initiation (%) 7 O (Ficus carica L., variety kadota, day 14) (series 1E) 1234.56 O O s SSto E SScd E cdSS cdSS S.CO -S S.CO -S OOOOOO K- C cod C cod S. S. S as o St. o St. 3 < a - Yoo N1 Sa E Sa E --- CD CDS (DS 9 Sv 9 S 9 9 ar' - CS- - CS Co - C Treatments FIG. 9B Patent Application Publication Jul. 7, 2011 Sheet 10 of 23 US 2011/O165096 A1 Mean Angiogenic Index (Ficus carica L., variety gold, day 14) (series 2A) (IDExcluding Zeros O Including Zeros C CC CO O CO CO - (O - 9E "as &3 - S- &3 38- SSN 9 SSN 2 &SS ds &SS S. OO E 8 CD r 2 CD 2 s CD S CD CD E CD E as is E E SC 92 3. CD c. c. C C Treatments FIG. 10A Angiogenesis Initiation (%) 70 (Ficus carica L., variety gold, day 14) (series 2A) 60 - 50 - 9. S 40 E 30 9 20 10 - O o g8 g8 SS SE SE SE w K- c) O O) O C S.N s. OnS as cco asto CNC - OS E2 D E NDg E o E S 8E Y . C2E 1. s pa pa ics in c. C ics Ya-Y CD - c. - c. Treatments FIG. 10B Patent Application Publication Jul. 7, 2011 Sheet 11 of 23 US 2011/O165096 A1 Mean Angiogenic Index Patent Application Publication Jul. 7, 2011 Sheet 12 of 23 US 2011/O165096 A1 Mean Angiogenic Index 7 (Ficus carica L., variety gold, day 14) (series 2C) |Excluding Zeros DIncluding Zeros c s 8 8 - - - sts v- CDcD 3S S c 3C S dCD3E S, 93ECD S, OSSS OSS) O CDk S2us c 8s is2 c. 89 LS2 SO 89 LS 8 asN E on5 E E S S CN CN Treatments FIG. 12A Angiogenesis Initiation (%) 40 - (Ficus carica L., variety gold, day 14) (Series 2C) o 3 SE SE g E SE SE SE E - S2 S 2 se S 5.5, 55. 3 is CD S. O O CD2 c. CD(2 v . CD2. c. 1. 2 C. 9 c. CD - C - O Y- - c. - c.5 O L. C. - - Treatments FIG. 12B Patent Application Publication Jul. 7, 2011 Sheet 13 of 23 US 2011/O165096 A1 Mean Angiogenic Index 10 -------------------------(Ficus carica L., variety magnolia, day 14) (series 3A) |Excluding Zeros DIncluding Zeros cE s > 3d > 38 E SEe- as8- > S SE > 3 SE o C (DS, CDS, CD se S CD so 9s 92 9. CD S S. L. S. 8 LS 8 S. S. -- C C CN CN Ye- CN CN Treatments FIG. 13A Angiogenesis initiation (%) 70 - (Ficus carica L., variety magnolia, day 14) (Series 3A) 60 50 9. 40 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - D - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 30 - 9.is 20 - 10 – O 9 5d Scd S Scd S SCO -S SCO S S(O -E SE(O - 8E aCw &> 2- & co2 &> 2 2& 2 &> 82 SB> 8 3.es CD CD 3s (D3C.
Load more

Recommended publications
  • Bergamot Oil: Botany, Production, Pharmacology
    Entry Bergamot Oil: Botany, Production, Pharmacology Marco Valussi 1,* , Davide Donelli 2 , Fabio Firenzuoli 3 and Michele Antonelli 2 1 Herbal and Traditional Medicine Practitioners Association (EHTPA), Norwich NR3 1HG, UK 2 AUSL-IRCCS Reggio Emilia, 42122 Reggio Emilia RE, Italy; [email protected] (D.D.); [email protected] (M.A.) 3 CERFIT, Careggi University Hospital, 50139 Firenze FI, Italy; fabio.firenzuoli@unifi.it * Correspondence: [email protected] Definition: Bergamot essential oil (BEO) is the result of the mechanical manipulation (cold pressing) of the exocarp (flavedo) of the hesperidium of Citrus limon (L.) Osbeck Bergamot Group (synonym Citrus × bergamia Risso & Poit.), resulting in the bursting of the oil cavities embedded in the flavedo and the release of their contents. It is chemically dominated by monoterpene hydrocarbons (i.e., limonene), but with significant percentages of oxygenated monoterpenes (i.e., linalyl acetate) and of non-volatile oxygen heterocyclic compounds (i.e., bergapten). Keywords: bergamot; citrus; essential oil; production; review 1. Introduction The taxonomy, and consequently the nomenclature, of the genus Citrus, is particularly complicated and has been rapidly changing in recent years (see Table1). For over 400 years, the centre of origin and biodiversity, along with the evolution and phylogeny of the Citrus species, have all been puzzling problems for botanists and the confusing and changing Citation: Valussi, M.; Donelli, D.; nomenclature of this taxon over the years can reflect intrinsic reproductive features of Firenzuoli, F.; Antonelli, M. Bergamot Oil: Botany, Production, the species included in this genus, the cultural and geographical issues, and the rapidly Pharmacology. Encyclopedia 2021, 1, evolving techniques used to clarify its phylogeny [1].
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • The Title Is in Blue Arial 32 Bold
    Recent Developments to Detect Lemon Juice Adulteration Authors: Ramin Jahromi, Hayley Pratt, Yang Zhou, Lars Reimann: Eurofins Nutrition Analysis Center, 2200 Rittenhouse St, Suite 175, Des Moines, IA 50321, USA ([email protected]) Dr. David A Hammond : Eurofins Scientific Analytics, Rue Pierre Adolphe Bobierre, F-44323, Nantes, France. Citropten Abstract: One of the possible adulterants of lemon juice is lime. The pattern of PMFs seen in lemon and lime juices are very different, which allow a much easier identification of substitution and/or addition of lime to lemon. This poster describes the method for the polymethoxyflavones “lime” markers. Introduction Discussion: Figure 2: PMF profile for lemon juice Unfortunately there is a long history of economic adulteration of fruit juices. The first well Experts from the European juice association (AIJN) have drawn up the typical ranges for a number publicized case of juice fraud was in 1989 with Beech-nut(1). This and subsequent events (10) of important juice components in 25 fruits and vegetables , which are extremely useful in the Citropten have meant that juice packers normally have a “verification” program for their raw assessment of the quality and authenticity of these products. They also working on a reference materials to ensure that they are authentic. Although in 2009 the FDA officially recognized guide for lime at present. food fraud as an emerging risk to the consumer, in fringe industries that use juice based Lemon and lime juices are normally adulterated by substitution of some or all of the juice solids by products, this risk had not been recognized and few companies have QA programs in place.
    [Show full text]
  • Phototherapy* Fototerapia*
    RevABDV81N1.qxd 17.02.06 15:55 Page 74 74 Artigo de Revisão Fototerapia* Phototherapy* Ida Duarte 1 Roberta Buense 2 Clarice Kobata 3 Resumo: Fototerapia é utilizada para tratar uma grande variedade de dermatoses. Desde o século pas- sado a fototerapia tem sido utilizada em várias modalidades, com irradiação UVA ou UVB. Está indica- da para todos os tipo de dermatoses inflamatórias e com período crônico de evolução, como vitiligo, pasoríase, parapsoríase, linfomas cutâneos de células T, eczemas crônicos, demonstrando bons resulta- dos terapêuticos. Pode ser utilizada como monoterapia ou associada a outras drogas, como retinóides, metotrexate, ciclos- porina, com objetivo de diminuir o tempo de tratamento e as doses das medicações mencionadas. Como os demais tipos de tratamento, a fototerapia apresenta algumas limitações, como a necessidade de equipamentos específicos, a adesão do paciente, a possibilidade de indicação ao paciente e a dose cumulativa de irradiação UV. A fototerapia deve ser conduzida com seguimento criterioso para a obtenção de resposta efetiva com poucos efeitos colaterais. Palavras-chave: Fototerapia; Inflamação; Raios ultravioleta; Terapia PUVA Abstract: Phototherapy has been used to treat a large variety of dermatoses since the past century. It is classified according to the type of irradiation (UVA or UVB). Phototherapy is indicated for all types of inflammatory and chronic skin diseases, such as vitiligo, psoriasis, parapsoriasis, cutaneous T-cell lymphomas and chronic eczemas, with good therapeutic results. It can be used as monotherapy or associated with others drugs, such as retinoids, methotrexate and cyclosporine, aiming to reduce length of treatment and doses. Like other treatments, phototherapy has some limitations - it requires specific equipment, patient's compliance, has restricted indications and leads to cumulative UV doses.
    [Show full text]
  • And Citrus Fruits
    Journal of the Science of Food and Agriculture J Sci Food Agric 87:2152–2163 (2007) Analysis of furanocoumarins in vegetables (Apiaceae) and citrus fruits (Rutaceae) Radek Peroutka, Veraˇ Schulzova,´ ∗ Petr Botek and Jana Hajslovˇ a´ Institute of Chemical Technology, Department of Food Chemistry and Analysis, Technicka´ 3, 166 28 Prague 6, Czech Republic Abstract: Several alternative approaches applicable for the analysis of furanocoumarins, toxic components occurring in some fruits and vegetables representing both Apiaceae and Rutaceae families, were tested in our study. Limits of detection (LODs) for angelicin, psoralen, bergapten, xanthotoxin, trioxsalen, isopimpinellin, sphondin, pimpinellin and isobergapten obtained by GC/MS (SIM) were in the range 0.01–0.08 µgg−1.Slightly higher LODs (0.02–0.20 µgg−1) were achieved by LC/MS–MS. The latter is the only alternative for analysis of bergamottin (LOD = 0.01 µgg−1) in citrus fruits because this furanocoumarin is unstable under GC conditions. Regardless of the determination step used, the repeatability of the measurements (expressed as RSD) did not exceed 10%. As shown in our study the levels of furanocoumarins in celery, celeriac, parsnip, carrot, lemon and other foods obtained at a retail market varied over a wide range; the highest contents were determined in parsnip, while the levels of these toxins in carrots and citrus pulps were relatively low. 2007 Society of Chemical Industry Keywords: furanocoumarins; GC/MS; LC/MS–MS; fruits; vegetables INTRODUCTION and fruit of some of these, e.g. figs, representing the Furanocoumarins are toxic secondary metabolites that last family, is also used for human consumption.
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Bergapten Improves Scopolamine-Induced Memory Impairment in Mice Via Cholinergic and Antioxidative Mechanisms
    fnins-14-00730 August 4, 2020 Time: 15:39 # 1 ORIGINAL RESEARCH published: 06 August 2020 doi: 10.3389/fnins.2020.00730 Bergapten Improves Scopolamine-Induced Memory Impairment in Mice via Cholinergic and Antioxidative Mechanisms Joanna Kowalczyk1,2, Łukasz Kurach2, Anna Boguszewska-Czubara3, Krystyna Skalicka-Wo´zniak4, Marta Kruk-Słomka5, Jacek Kurzepa3, Małgorzata Wydrzynska-Ku´zma5, Grazyna˙ Biała5, Adrianna Skiba4 and Barbara Budzynska´ 2* 1 Chair and Department of Applied Pharmacy, Medical University of Lublin, Lublin, Poland, 2 Independent Laboratory of Behavioral Studies, Medical University of Lublin, Lublin, Poland, 3 Chair and Department of Medicinal Chemistry, Medical University of Lublin, Lublin, Poland, 4 Chair and Department of Pharmacognosy with Medicinal Plant Unit, Medical University Edited by: of Lublin, Lublin, Poland, 5 Chair and Department of Pharmacology and Pharmacodynamics, Medical University of Lublin, Maria Javier Ramirez, Lublin, Poland University of Navarra, Spain Reviewed by: Patrizio Blandina, Bergapten is a furanocoumarin naturally occurring in the Apiaceae family and it is a well- University of Florence, Italy known photosensitizing agent used in photochemotherapy. In this study, we investigated Mariela Fernanda Perez, the influence of bergapten on cognitive function and mechanism underlying these effects National University of Córdoba, Argentina in scopolamine-induced memory impairment in male Swiss mice. The passive avoidance *Correspondence: test was used to evaluate the efficiency of memory acquisition and consolidation. Barbara Budzynska´ The results demonstrated that both single and repeated administration of bergapten [email protected] improved not only the acquisition but also consolidation of memory. The behavioral Specialty section: tests showed that bergapten prevented memory impairment induced by administration This article was submitted to of scopolamine.
    [Show full text]
  • Wo 2008/127291 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 23 October 2008 (23.10.2008) WO 2008/127291 A2 (51) International Patent Classification: Jeffrey, J. [US/US]; 106 Glenview Drive, Los Alamos, GOlN 33/53 (2006.01) GOlN 33/68 (2006.01) NM 87544 (US). HARRIS, Michael, N. [US/US]; 295 GOlN 21/76 (2006.01) GOlN 23/223 (2006.01) Kilby Avenue, Los Alamos, NM 87544 (US). BURRELL, Anthony, K. [NZ/US]; 2431 Canyon Glen, Los Alamos, (21) International Application Number: NM 87544 (US). PCT/US2007/021888 (74) Agents: COTTRELL, Bruce, H. et al.; Los Alamos (22) International Filing Date: 10 October 2007 (10.10.2007) National Laboratory, LGTP, MS A187, Los Alamos, NM 87545 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY,BZ, CA, CH, (30) Priority Data: CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, 60/850,594 10 October 2006 (10.10.2006) US ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicants (for all designated States except US): LOS LR, LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, MW, ALAMOS NATIONAL SECURITY,LLC [US/US]; Los MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, Alamos National Laboratory, Lc/ip, Ms A187, Los Alamos, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, NM 87545 (US).
    [Show full text]
  • Reseptregisteret 2011-2015 / Norwegian Prescription
    legemiddel- statistikk 2016:2 Reseptregisteret 2011–2015 The Norwegian Prescription Database 2011–2015 legemiddel- statistikk 2016:2 Reseptregisteret 2011–2015 The Norwegian Prescription Database 2011–2015 Christian Berg Hege Salvesen Blix Olaug Fenne Kari Jansdotter Husabø Randi Selmer Sissel Torheim Kari Furu Rapport 2016:2 Nasjonalt folkehelseinstitutt / The Norwegian Institute of Public Health Tittel/Title: Reseptregisteret 2011–2015 The Norwegian Prescription Database 2011–2015 Redaktør/Editor: Christian Berg Forfattere/Authors: Christian Berg Hege Salvesen Blix Olaug Fenne Kari Jansdotter Husabø Randi Selmer Sissel Torheim Kari Furu Publisert av / Published by: Folkehelseinstituttet Postboks 4404 Nydalen NO-0403 Norway Tel: + 47 21 07 70 00 E-mail: [email protected] www.fhi.no Design/Layout Houston911 Acknowledgement: Julie D.W. Johansen (English version) Forsideillustrasjon / Front page illustration: Dreamstime Bestilling/Order: Kun tilgjengelig som PDF. Lastes ned fra www.fhi.no Only available as PDF from www.fhi.no ISSN: 1890-9647 ISBN: 978-82-8082-714-2 Tidligere utgave / Previous edition: 2008: Reseptregisteret 2004–2007 / The Norwegian Prescription Database 2004–2007 2009: Legemiddelstatistikk 2009:2: Reseptregisteret 2004–2008 / The Norwegian Prescription Database 2004–2008 2010: Legemiddelstatistikk 2010:2: Reseptregisteret 2005–2009. Tema: Vanedannende legemidler / The Norwegian Prescription Database 2005–2009. Topic: Addictive drugs 2011: Legemiddelstatistikk 2011:2: Reseptregisteret 2006–2010 / The Norwegian Prescription Database 2006–2010 2012: Legemiddelstatistikk 2012:2: Reseptregisteret 2007–2011 / The Norwegian Prescription Database 2007–2011 2013: Legemiddelstatistikk 2013:2: Reseptregisteret 2008–2012 / The Norwegian Prescription Database 2008–2012 2014: Legemiddelstatistikk 2014:2: Reseptregisteret 2009–2013. / The Norwegian Prescription Database 2009–2013 2015: Legemiddelstatistikk 2015:2: Reseptregisteret 2010–2014.
    [Show full text]
  • Analytical Methods for the Determination of Anti-Psoriatic Drugs - a Review
    Acta Scientific Pharmaceutical Sciences (ISSN: 2581-5423) Volume 4 Issue 2 February 2020 Review Article Analytical Methods for the Determination of Anti-Psoriatic Drugs - A Review Sistla Mounica Pratyusha* and Choppala Asha Deepti Department of Pharmaceutical Analysis and Quality Assurance, GITAM Institute Received: January 20, 2020 of Pharmacy, GITAM (Deemed to be) University, Visakhapatnam, Andhra Pradesh, Published: January 31, 2020 India © All rights are reserved by Sistla Mounica *Corresponding Author: Sistla Mounica Pratyusha, Department of Pharma- Pratyusha and Choppala Asha Deepti. ceutical Analysis and Quality Assurance, GITAM Institute of Pharmacy, GITAM (Deemed to be) University, Visakhapatnam, Andhra Pradesh, India. DOI: 10.31080/ASPS.2020.04.0490 Abstract Psoriasis is a long-lasting autoimmune disease characterized by patches of abnormal skin. Typical psoriatic scales are in thick, red patches. Sometimes, these patches will crack and bleed. Psoriasis is the result of a sped-up skin production process. Some of the drugs used in the treatment of psoriasis are Acitretin, Etretinate, Bergapten, Methoxsalen, Tazarotene, Calcipotriol, Anthralin etc. A brief review of the analytical methods developed for the determination of drugs used for the treatment of Psoriasis was discussed in the present study. Keywords: Acitretin; Etretinate; Bergapten Introduction Psoriasis is a chronic autoimmune condition that causes the rapid build-up of skin cells. This build-up of cells causes scaling on the skin’s surface. Typically, skin cells grow deep in the skin and slowly rise to the surface. The typical life cycle of a skin cell is one month. Some of the drugs used in the treatment of psoriasis: Acitretin, Etretinate, Bergapten, Methoxsalen, Tazarotene, Calci- potriol, Anthralin and the chemical structures of these drugs were - termination of these drugs were summarized in table 1.
    [Show full text]
  • Bergapten Drives Autophagy Through the Up-Regulation of PTEN
    De Amicis et al. Molecular Cancer (2015) 14:130 DOI 10.1186/s12943-015-0403-4 RESEARCH Open Access Bergapten drives autophagy through the up-regulation of PTEN expression in breast cancer cells Francesca De Amicis1,2†, Saveria Aquila1,2*†, Catia Morelli1, Carmela Guido2, Marta Santoro2, Ida Perrotta3, Loredana Mauro1, Francesca Giordano1, Alessandra Nigro3, Sebastiano Andò1,2* and Maria L. Panno1* Abstract Background: Bergapten (5-methoxypsoralen), a natural psoralen derivative present in many fruits and vegetables, has shown antitumoral effects in a variety of cell types. In this study, it has been addressed how Bergapten in breast cancer cells induces autophagic process. Results: In MCF7 and ZR-75 breast cancer cells Bergapten exhibited anti-survival response by inducing the autophagic process increasing Beclin1, PI3KIII, UVRAG, AMBRA expression and conversion of LC3-I to LC3-II. LC3-GFP, Acridine orange assay and transmission electron microscopy even confirmed the increased autophagosome formations in treated cells. Bergapten-induced autophagy is dependent by PTEN up-regulation, since silencing this gene, the induction of Beclin1 and the p-AKT/p-mTOR signal down-regulation were reversed. PTEN is transcriptionally regulated by Bergapten through the involvement of p38MAPK/NF-Y, as evidenced by the use of p38MAPK inhibitor SB203580, site-direct mutagenesis of NF-Y element and NF-Y siRNA. Furthermore NF-Y knockdown prevented Bergapten-induced acid vesicular organelle accumulations (AVOs), strengthening the role of this element in mediating autophagy. Conclusions: Our data indicate PTEN as a key target of Bergapten action in breast cancer cells for the induction of autophagy. These findings add further details on the mechanism of action of Bergapten, therefore suggesting that phytochemical compounds may be implemented in the novel strategies for breast cancer treatment.
    [Show full text]
  • The Psoralens Adversely Affect Reproductive Function in Male Wistar Rats
    Reproductive Toxicology 15 (2001) 137–144 www.elsevier.com/locate/reprotox The psoralens adversely affect reproductive function in male wistar rats Moussa M. Diawaraa,*, Kathryn J. Chavezb, Doug Simplemana, David E. Williamsc, Michael R. Franklind, Patricia B. Hoyere aDepartment of Biology, University of Southern Colorado, Pueblo, CO 81001, USA bDepartment of Comparative Environmental Toxicology, Cornell University, Ithaca, NY 14853, USA cDepartment of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR 97331, USA dDepartment of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA eDepartment of Physiology, University of Arizona, Tucson, AR 85721, USA Received 3 October 2000; received in revised form 3 November 2000; accepted 23 December 2000 This research was supported, in part, by the National Institute of Environmental Health Sciences (NIH/NIEHS) grant ES00288 (to MMD), grant ADCRC #9808 (to PBH), and The University of Southern Colorado’s Faculty Scholarly Activity Grant. Abstract The psoralens occur naturally in produce and are widely used in skin therapy. Studies show that 5-methoxypsoralen and 8-methoxy- psoralen reduced birth rates in rats. We determined the effect of psoralens on reproductive function in male rats. Male Wistar rats were dosed daily with 5-methoxypsoralen or 8-methoxypsoralen (75 or 150 mg/kg, p.o.), or vehicle control. Treated males had significantly smaller pituitary glands, fewer sperm per ejaculate, and fewer sperm in the vasa defferentia and epididymides than controls. Dosing significantly elevated levels of testosterone and increased relative testis weight, but did not directly affect testicular weight. Females bred to dosed males required more time to become pregnant, and these males required more breeding attempts.
    [Show full text]